Moderna (MRNA) has seen its stock price plummet approximately 90% since its peak in 2021, recently trading around $53. The company’s revenue has drastically declined, falling about 90% from pandemic highs, prompting a revaluation of its status from a growing vaccine developer to a weakening biotech firm.
Core to Moderna’s potential recovery is its pipeline, particularly its personalized cancer vaccine developed in collaboration with Merck. Early data indicates significant reductions in recurrence rates, with crucial Phase 3 results anticipated, which could significantly alter the company’s outlook. Additionally, Moderna has considerable cash reserves that could support its ongoing projects.
If the cancer vaccine proves successful, analysts suggest Moderna’s stock could rise to around $100 per share, reflecting its potential as an oncology platform rather than solely a COVID-19 vaccine company. Investors remain cautious, noting risks such as continued revenue decline and regulatory challenges.
